Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuroscientific BiopharmaceuticalsASX:NSB Pretax Margin % is -534.28% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 943 Biotechnology companies, Neuroscientific Biopharmaceuticals ranks worse than 78.58% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Neuroscientific Biopharmaceuticals Pretax Margin % Related Terms
Neuroscientific Biopharmaceuticals Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NSB vs VRTX, REGN, RVMD: Pretax Margin % Comparison
For the Biotechnology subindustry, Neuroscientific Biopharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuroscientific Biopharmaceuticals Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuroscientific Biopharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Neuroscientific Biopharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuroscientific Biopharmaceuticals (ASX:NSB) has a Pretax Margin % of -534.28% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Neuroscientific Biopharmaceuticals and its competitors. According to the industry distribution chart, Neuroscientific Biopharmaceuticals ranks #741 out of 943 companies in the Biotechnology industry, placing it in the top 78.6%.
Is Neuroscientific Biopharmaceuticals' Pretax Margin % too high?
Neuroscientific Biopharmaceuticals' current Pretax Margin % is -534.28%. Based on the distribution chart, Neuroscientific Biopharmaceuticals ranks #741 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Neuroscientific Biopharmaceuticals' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuroscientific Biopharmaceuticals ranks #741 out of 943 companies for Pretax Margin %. This places Neuroscientific Biopharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Neuroscientific Biopharmaceuticals and its competitors. Neuroscientific Biopharmaceuticals's current Pretax Margin % is -534.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuroscientific Biopharmaceuticals stock overvalued right now?
Neuroscientific Biopharmaceuticals (ASX:NSB) has a current Pretax Margin % of -534.28%. The current Pretax Margin % is -534.28%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Neuroscientific Biopharmaceuticals (ASX:NSB), the current Pretax Margin % is -534.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and treatments for neurodegenerative diseases through preclinical studies of patented technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NSB has been successfully added to your 
